Morepen Laboratories gains CDSCO approval for Resmetirom bioequivalence studies, positioning the company for global NASH ...

Morepen Laboratories has got clearance from Subject Expert Committee (SEC) of Central Drugs Standard Control Organization (CDSCO) to conduct Bioequivalence (BE) studies for Resmetirom 60 mg, 80 mg and ...

Morepen Laboratories Ltd. has got clearance from Subject Expert Committee of CDSCO to conduct Bioequivalence studies for ...

Zurich (Switzerland), - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced ...

The liver can function at a reduced capacity for a long time before showing signs of distress. Read on as we list some of the ...

A devoted wife and mother, the woman tragically lost her life in a road accident. Yet, in a remarkable act of generosity, her ...

A drug candidate, previously successful at treating severe fatty liver disease, reduces atherosclerosis - a primary driver of cardiovascular death worldwide - in large mammals, a study suggests.

A drug candidate, previously successful at treating severe fatty liver disease, reduces atherosclerosis—a primary driver of ...